Table 1. Clinical characteristics of patients by ARC study.
| ARC1 2006–7 (n = 107) | ARC2 2008–9 (n = 136) | p-value | |
| Age | 28 (20–41) | 25 (20–35) | 0.04 |
| Male gender | 68 (64%) | 107 (79%) | 0.01 |
| History of malaria in previous 12 mos | 55 (41%) | 45 (33%) | 0.01 |
| Duration of symptoms (days) | 3 (3–5) | 3 (3–4) | 0.07 |
| Baseline parasitemia (/µl) | 6,562 (2,339–19,849) | 12,748 (5,090–34,730) | <0.001* |
| Baseline parasitemia group | |||
| 0–10 K | 68 (64%) | 60 (44%) | |
| 10 K–100 K | 39 (36%) | 69 (51%) | |
| >100 K | 0 (0%) | 7 (5%) | |
| Baseline temperature (°C) | 38.0 (37.2–38.8) | 38.1 (37.4–38.9) | 0.24 |
| Fever at admission (T>37.9°C) | 58 (54%) | 77 (57%) | 0.71 |
| Baseline hematocrit (%) | 38 (33–41) | 39 (37–43) | 0.01 |
| Presence of Pf gametocytes on admit | 23 (22%) | 20 (15%) | 0.17 |
| Presence of Pf gametocytes on day 14 | 16 (15%) | 12 (9%) | 0.14 |
| Presence of Pf gametocytes anytime during follow-up | 40 (37%) | 36 (26%) | 0.07 |
| Parasite clearance time (hrs) | 64 (43–91) | 78 (60–90) | 0.01 |
| Fever clearance time | 9 (0–29) | 16 (7–29) | 0.01 |
| Developed Pv parasitemia during follow-up** | 32 (30%) | 27 (20%) | 0.07 |
| Developed Pv parasitemia by day 28 of follow-up | 32 (30%) | 15 (11%) | <0.001 |
| Developed Pf recurrence | 4 (3.8%) | 8 (5.9%) | 0.44 |
Values are reported as median and interquartile ranges unless otherwise specified.
*The difference in baseline parasitemia reflects a difference in the inclusion criteria between the two trials, with no minimum parasitemia required in ARC1.
**Follow-up was for 28 days and 42 days for ARC1 and ARC2, respectively.